Clinical trial · Interventional
Combined Treatment of RFA and Sorafenib on Recurrent HCC
Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Radiofrequency Ablation | — | UNRESOLVED | — |
| Sorafenib | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RFA | Other | — | UNRESOLVED |
| RFA + Sorafenib | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- RFA+Sorafenib
- description
- to treat recurrent HCC both with RFA and Sorafenib
- interventionNames
- Other: RFA + Sorafenib
- type
- ACTIVE_COMPARATOR
- label
- RFA group
- description
- To treat recurrent HCC with RFA
- interventionNames
- Other: RFA
Primary outcomes (1)
- measure
- time interval between new lessions emerging after the first HCC recurrence
- timeFrame
- 3 year
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * recurrent HCC after curative resection * without gender restriction * age between 18 to 75 years * The liver function showed no worse than Child-Pugh B * tumor nodes were less than 5cm and no more than 3 nodules Exclusion Criteria: * Pregnancy patients * With extrahepatic tumor or lymphnode metastasis * Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava
References
Publications (0)
Data not yet available